Spero Therapeutics Inc (SPRO) — Cash Flow-to-Debt Ratio
Spero Therapeutics Inc (SPRO) has a Cash Flow-to-Debt Ratio of -0.84x as of December 2025, meaning its operating cash flow of $-8.35 Million could theoretically repay -1% of its total liabilities ($9.90 Million) in one year. See how much free cash does Spero Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Spero Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Spero Therapeutics Inc across 11 annual periods. Also explore Spero Therapeutics Inc (SPRO) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Spero Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for Spero Therapeutics Inc. For market capitalisation and broader financial context, see Spero Therapeutics Inc (SPRO) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.28x | $-12.62 Million | $9.90 Million | ▼ -250.5% |
| 2024 | -0.36x | $-23.44 Million | $64.42 Million | ▲ +16.7% |
| 2023 | -0.44x | $-32.99 Million | $75.50 Million | ▼ -176.3% |
| 2022 | -0.16x | $-7.73 Million | $48.87 Million | ▲ +79.6% |
| 2021 | -0.78x | $-64.35 Million | $82.78 Million | ▲ +80.6% |
| 2020 | -4.01x | $-85.87 Million | $21.41 Million | ▼ -152.8% |
| 2019 | -1.59x | $-50.02 Million | $31.53 Million | ▲ +47.3% |
| 2018 | -3.01x | $-39.62 Million | $13.15 Million | ▲ +34.3% |
| 2017 | -4.59x | $-39.11 Million | $8.52 Million | ▼ -17.4% |
| 2016 | -3.91x | $-28.96 Million | $7.41 Million | ▼ -202.3% |
| 2015 | -1.29x | $-9.61 Million | $7.43 Million | — |